|
1
|
Baran CP, Zeigler MM, Tridandapani S and
Marsh CB: The role of ROS and RNS in regulating life and death of
blood monocytes. Curr Pharm Des. 10:855–866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zorov DB, Juhaszova M and Sollott SJ:
Mitochondrial ROS-induced ROS release: an update and review.
Biochim Biophys Acta. 1757:509–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zelko IN, Mariani TJ and Folz RJ:
Superoxide dismutase multigene family: a comparison of the CuZn-SOD
(SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures,
evolution, and expression. Free Radic Biol Med. 33:337–349. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wilcox CS: Reactive oxygen species: roles
in blood pressure and kidney function. Curr Hypertens Rep.
4:160–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marks PA: Thioredoxin in cancer - role of
histone deacetylase inhibitors. Semin Cancer Biol. 16:436–443.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen TJ, Jeng JY, Lin CW, Wu CY and Chen
YC: Quercetin inhibition of ROS-dependent and -independent
apoptosis in rat glioma C6 cells. Toxicology. 223:113–126. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dasmahapatra G, Rahmani M, Dent P and
Grant S: The tyrphostin adaphostin interacts synergistically with
proteasome inhibitors to induce apoptosis in human leukemia cells
through a reactive oxygen species (ROS)-dependent mechanism. Blood.
107:232–240. 2006. View Article : Google Scholar
|
|
8
|
Wallach-Dayan SB, Izbicki G, Cohen PY,
Gerstl-Golan R, Fine A and Breuer R: Bleomycin initiates apoptosis
of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J
Physiol Lung Cell Mol Physiol. 290:L790–L796. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Waxman S and Anderson KC: History of the
development of arsenic derivatives in cancer therapy. Oncologist.
6(Suppl 2): 3–10. 2001. View Article : Google Scholar
|
|
10
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al: Use of arsenic
trioxide (As2O3) in the treatment of acute promyelocytic leukemia
(APL): II. Clinical efficacy and pharmacokinetics in relapsed
patients. Blood. 89:3354–3360. 1997.PubMed/NCBI
|
|
11
|
Soignet SL, Maslak P, Wang ZG, Jhanwar S,
Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J,
Scheinberg DA, et al: Complete remission after treatment of acute
promyelocytic leukemia with arsenic trioxide. N Engl J Med.
339:1341–1348. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park WH, Seol JG, Kim ES, Hyun JM, Jung
CW, Lee CC, Kim BK and Lee YY: Arsenic trioxide-mediated growth
inhibition in MC/CAR myeloma cells via cell cycle arrest in
association with induction of cyclin-dependent kinase inhibitor,
p21, and apoptosis. Cancer Res. 60:3065–3071. 2000.
|
|
13
|
Zhang W, Ohnishi K, Shigeno K, Fujisawa S,
Naito K, Nakamura S, Takeshita K, Takeshita A and Ohno R: The
induction of apoptosis and cell cycle arrest by arsenic trioxide in
lymphoid neoplasms. Leukemia. 12:1383–1391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller WH Jr, Schipper HM, Lee JS, Singer
J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer
Res. 62:3893–3903. 2002.PubMed/NCBI
|
|
15
|
Hyun Park W, Hee Cho Y, Won Jung C, Oh
Park J, Kim K, Hyuck Im Y, Lee MH, Ki Kang W and Park K: Arsenic
trioxide inhibits the growth of A498 renal cell carcinoma cells via
cell cycle arrest or apoptosis. Biochem Biophys Res Commun.
300:230–235. 2003.
|
|
16
|
Seol JG, Park WH, Kim ES, Jung CW, Hyun
JM, Kim BK and Lee YY: Effect of arsenic trioxide on cell cycle
arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res
Commun. 265:400–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uslu R, Sanli UA, Sezgin C, Karabulut B,
Terzioglu E, Omay SB and Goker E: Arsenic trioxide-mediated
cytotoxicity and apoptosis in prostate and ovarian carcinoma cell
lines. Clin Cancer Res. 6:4957–4964. 2000.PubMed/NCBI
|
|
18
|
Oketani M, Kohara K, Tuvdendorj D,
Ishitsuka K, Komorizono Y, Ishibashi K and Arima T: Inhibition by
arsenic trioxide of human hepatoma cell growth. Cancer Lett.
183:147–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pu YS, Hour TC, Chen J, Huang CY, Guan JY
and Lu SH: Cytotoxicity of arsenic trioxide to transitional
carcinoma cells. Urology. 60:346–350. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakagawa Y, Akao Y, Morikawa H, Hirata I,
Katsu K, Naoe T, Ohishi N and Yagi K: Arsenic trioxide-induced
apoptosis through oxidative stress in cells of colon cancer cell
lines. Life Sci. 70:2253–2269. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li M, Cai JF and Chiu JF: Arsenic induces
oxidative stress and activates stress gene expressions in cultured
lung epithelial cells. J Cell Biochem. 87:29–38. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Baj G, Arnulfo A, Deaglio S, Mallone R,
Vigone A, De Cesaris MG, Surico N, Malavasi F and Ferrero E:
Arsenic trioxide and breast cancer: analysis of the apoptotic,
differentiative and immunomodulatory effects. Breast Cancer Res
Treat. 73:61–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Woo SH, Park IC, Park MJ, Lee HC, Lee SJ,
Chun YJ, Lee SH, Hong SI and Rhee CH: Arsenic trioxide induces
apoptosis through a reactive oxygen species-dependent pathway and
loss of mitochondrial membrane potential in HeLa cells. Int J
Oncol. 21:57–63. 2002.
|
|
24
|
Zhang TC, Cao EH, Li JF, Ma W and Qin JF:
Induction of apoptosis and inhibition of human gastric cancer
MGC-803 cell growth by arsenic trioxide. Eur J Cancer.
35:1258–1263. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim HR, Kim EJ, Yang SH, Jeong ET, Park C,
Kim SJ, Youn MJ, So HS and Park R: Combination treatment with
arsenic trioxide and sulindac augments their apoptotic potential in
lung cancer cells through activation of caspase cascade and
mitochondrial dysfunction. Int J Oncol. 28:1401–1408. 2006.
|
|
26
|
Li JJ, Tang Q, Li Y, Hu BR, Ming ZY, Fu Q,
Qian JQ and Xiang JZ: Role of oxidative stress in the apoptosis of
hepatocellular carcinoma induced by combination of arsenic trioxide
and ascorbic acid. Acta Pharmacol Sin. 27:1078–1084. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou WC, Jie C, Kenedy AA, Jones RJ, Trush
MA and Dang CV: Role of NADPH oxidase in arsenic-induced reactive
oxygen species formation and cytotoxicity in myeloid leukemia
cells. Proc Natl Acad Sci USA. 101:4578–4583. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu J, Chew EH and Holmgren A: Targeting
thioredoxin reductase is a basis for cancer therapy by arsenic
trioxide. Proc Natl Acad Sci USA. 104:12288–12293. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chouchane S and Snow ET: In vitro effect
of arsenical compounds on glutathione-related enzymes. Chem Res
Toxicol. 14:517–522. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu XX, Ogawa O and Kakehi Y: Enhancement
of arsenic trioxide-induced apoptosis in renal cell carcinoma cells
by L-buthionine sulfoximine. Int J Oncol. 24:1489–1497.
2004.PubMed/NCBI
|
|
31
|
Kitamura K, Minami Y, Yamamoto K, Akao Y,
Kiyoi H, Saito H and Naoe T: Involvement of CD95-independent
caspase 8 activation in arsenic trioxide-induced apoptosis.
Leukemia. 14:1743–1750. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dai J, Weinberg RS, Waxman S and Jing Y:
Malignant cells can be sensitized to undergo growth inhibition and
apoptosis by arsenic trioxide through modulation of the glutathione
redox system. Blood. 93:268–277. 1999.PubMed/NCBI
|
|
33
|
Han YH, Kim SZ, Kim SH and Park WH:
Induction of apoptosis in arsenic trioxide-treated lung cancer A549
cells by buthionine sulfoximine. Mol Cells. 26:158–164.
2008.PubMed/NCBI
|
|
34
|
Kito M, Akao Y, Ohishi N, Yagi K and
Nozawa Y: Arsenic trioxide-induced apoptosis and its enhancement by
buthionine sulfoximine in hepatocellular carcinoma cell lines.
Biochem Biophys Res Commun. 291:861–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maeda H, Hori S, Ohizumi H, Segawa T,
Kakehi Y, Ogawa O and Kakizuka A: Effective treatment of advanced
solid tumors by the combination of arsenic trioxide and
L-buthionine-sulfoximine. Cell Death Differ. 11:737–746. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Petty RD, Nicolson MC, Kerr KM,
Collie-Duguid E and Murray GI: Gene expression profiling in
non-small cell lung cancer: from molecular mechanisms to clinical
application. Clin Cancer Res. 10:3237–3248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jin HO, Yoon SI, Seo SK, Lee HC, Woo SH,
Yoo DH, Lee SJ, Choe TB, An S, Kwon TJ, et al: Synergistic
induction of apoptosis by sulindac and arsenic trioxide in human
lung cancer A549 cells via reactive oxygen species-dependent
down-regulation of survivin. Biochem Pharmacol. 72:1228–1236. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Han YH, Kim SZ, Kim SH and Park WH:
Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a
G2 arrest of the cell cycle and apoptosis accompanied with the
depletion of GSH. Cancer Lett. 270:40–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han YH, Kim SH, Kim SZ and Park WH:
Apoptosis in arsenic trioxide-treated Calu-6 lung cells is
correlated with the depletion of GSH levels rather than the changes
of ROS levels. J Cell Biochem. 104:862–878. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Han YH, Moon HJ, You BR, Kim SZ, Kim SH
and Park WH: Effects of arsenic trioxide on cell death, reactive
oxygen species and glutathione levels in different cell types. Int
J Mol Med. 25:121–128. 2010.PubMed/NCBI
|
|
41
|
Bailey HH: L-S,R-buthionine sulfoximine:
historical development and clinical issues. Chem Biol Interact.
111–112:239–254. 1998.PubMed/NCBI
|
|
42
|
Han YH, Kim SH, Kim SZ and Park WH:
Caspase inhibitor decreases apoptosis in pyrogallol-treated lung
cancer Calu-6 cells via the prevention of GSH depletion. Int J
Oncol. 33:1099–1105. 2008.PubMed/NCBI
|
|
43
|
Han YH, Kim SZ, Kim SH and Park WH:
Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via
cell cycle arrest and caspase-independent apoptosis. Am J Physiol
Renal Physiol. 293:F511–F520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Elbashir SM, Harborth J, Lendeckel W,
Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs
mediate RNA interference in cultured mammalian cells. Nature.
411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kang YH, Yi MJ, Kim MJ, Park MT, Bae S,
Kang CM, Cho CK, Park IC, Park MJ, Rhee CH, et al:
Caspase-independent cell death by arsenic trioxide in human
cervical cancer cells: reactive oxygen species-mediated
poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing
factor release from mitochondria. Cancer Res. 64:8960–8967. 2004.
View Article : Google Scholar
|
|
47
|
Jing Y, Dai J, Chalmers-Redman RM, Tatton
WG and Waxman S: Arsenic trioxide selectively induces acute
promyelocytic leukemia cell apoptosis via a hydrogen
peroxide-dependent pathway. Blood. 94:2102–2111. 1999.PubMed/NCBI
|
|
48
|
Haga N, Fujita N and Tsuruo T: Involvement
of mitochondrial aggregation in arsenic trioxide (As2O3)-induced
apoptosis in human glioblastoma cells. Cancer Sci. 96:825–833.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yedjou CG, Rogers C, Brown E and Tchounwou
PB: Differential effect of ascorbic acid and n-acetyl-L-cysteine on
arsenic trioxide-mediated oxidative stress in human leukemia
(HL-60) cells. J Biochem Mol Toxicol. 22:85–92. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bahlis NJ, McCafferty-Grad J,
Jordan-McMurry I, Neil J, Reis I, Kharfan-Dabaja M, Eckman J,
Goodman M, Fernandez HF, Boise LH, et al: Feasibility and
correlates of arsenic trioxide combined with ascorbic acid-mediated
depletion of intracellular glutathione for the treatment of
relapsed/refractory multiple myeloma. Clin Cancer Res. 8:3658–3668.
2002.
|
|
51
|
Grad JM, Bahlis NJ, Reis I, Oshiro MM,
Dalton WS and Boise LH: Ascorbic acid enhances arsenic
trioxide-induced cytotoxicity in multiple myeloma cells. Blood.
98:805–813. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Campbell RA, Sanchez E, Steinberg JA,
Baritaki S, Gordon M, Wang C, Shalitin D, Chen H, Pang S, Bonavida
B, et al: Antimyeloma effects of arsenic trioxide are enhanced by
melphalan, bortezomib and ascorbic acid. Br J Haematol.
138:467–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yedjou C, Thuisseu L, Tchounwou C, Gomes
M, Howard C and Tchounwou P: Ascorbic acid potentiation of arsenic
trioxide anticancer activity against acute promyelocytic leukemia.
Arch Drug Inf. 2:59–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Biswas S, Zhao X, Mone AP, Mo X, Vargo M,
Jarjoura D, Byrd JC and Muthusamy N: Arsenic trioxide and ascorbic
acid demonstrate promising activity against primary human CLL cells
in vitro. Leuk Res. 34:925–931. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gallegos A, Gasdaska JR, Taylor CW,
Paine-Murrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM
and Powis G: Transfection with human thioredoxin increases cell
proliferation and a dominant-negative mutant thioredoxin reverses
the transformed phenotype of human breast cancer cells. Cancer Res.
56:5765–5770. 1996.
|
|
56
|
Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y,
Nakamura H, Yodoi J, Kato K and Noguchi S: High thioredoxin
expression is associated with resistance to docetaxel in primary
breast cancer. Clin Cancer Res. 11:8425–8430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Epperly MW, Epstein CJ, Travis EL and
Greenberger JS: Decreased pulmonary radiation resistance of
manganese superoxide dismutase (MnSOD)-deficient mice is corrected
by human manganese superoxide dismutase-Plasmid/Liposome (SOD2-PL)
intratracheal gene therapy. Radiat Res. 154:365–374. 2000.
View Article : Google Scholar
|
|
58
|
Estrela JM, Ortega A and Obrador E:
Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci.
43:143–181. 2006. View Article : Google Scholar
|
|
59
|
Higuchi Y: Glutathione depletion-induced
chromosomal DNA fragmentation associated with apoptosis and
necrosis. J Cell Mol Med. 8:455–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ramos AM, Fernandez C, Amran D, Esteban D,
de Blas E, Palacios MA and Aller P: Pharmacologic inhibitors of
extracellular signal-regulated kinase (ERKs) and c-Jun
NH(2)-terminal kinase (JNK) decrease glutathione content and
sensitize human promonocytic leukemia cells to arsenic
trioxide-induced apoptosis. J Cell Physiol. 209:1006–1015. 2006.
View Article : Google Scholar
|
|
61
|
Wang T, Ma LM, Zhang HP, Wang HW, Yang LH
and Qiao ZH: The effect of arsenic trioxide (As2O3) combined with
BSO on K562/ADM cell and its mechanisms. Zhonghua Xue Ye Xue Za
Zhi. 28:438–443. 2007.(In Chinese).
|
